Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.64 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.64 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.64 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.64 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.64 |
| ▸ | APP | P05067 | 14/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755397 | 1.00 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14768524 | 1.00 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14753401 | 1.00 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14768494 | 0.90 | APP (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14753443 | 0.90 | APP (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14773173 | 0.90 | APP (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14751837 | 0.90 | APP (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14773099 | 0.90 | APP (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12210262 | 0.90 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12207663 | 0.88 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SNCA, HTT, PARK7 | PSEN1 16/4885PSEN2 5/4885APH1B 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.